Cargando…
SARS-CoV-2 Inhibition by Sulfonated Compounds
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) depends on angiotensin converting enzyme 2 (ACE2) for cellular entry, but it might also rely on attachment receptors such as heparan sulfates. Several groups have recently demonstrated an affinity of the SARS-CoV2 spike protein for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760145/ https://www.ncbi.nlm.nih.gov/pubmed/33265927 http://dx.doi.org/10.3390/microorganisms8121894 |
_version_ | 1783627263986630656 |
---|---|
author | Gasbarri, Matteo V’kovski, Philip Torriani, Giulia Thiel, Volker Stellacci, Francesco Tapparel, Caroline Cagno, Valeria |
author_facet | Gasbarri, Matteo V’kovski, Philip Torriani, Giulia Thiel, Volker Stellacci, Francesco Tapparel, Caroline Cagno, Valeria |
author_sort | Gasbarri, Matteo |
collection | PubMed |
description | Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) depends on angiotensin converting enzyme 2 (ACE2) for cellular entry, but it might also rely on attachment receptors such as heparan sulfates. Several groups have recently demonstrated an affinity of the SARS-CoV2 spike protein for heparan sulfates and a reduced binding to cells in the presence of heparin or heparinase treatment. Here, we investigated the inhibitory activity of several sulfated and sulfonated molecules, which prevent interaction with heparan sulfates, against vesicular stomatitis virus (VSV)-pseudotyped-SARS-CoV-2 and the authentic SARS-CoV-2. Sulfonated cyclodextrins and nanoparticles that have recently shown broad-spectrum non-toxic virucidal activity against many heparan sulfates binding viruses showed inhibitory activity in the micromolar and nanomolar ranges, respectively. In stark contrast with the mechanisms that these compounds present for these other viruses, the inhibition against SARS-CoV-2 was found to be simply reversible. |
format | Online Article Text |
id | pubmed-7760145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77601452020-12-26 SARS-CoV-2 Inhibition by Sulfonated Compounds Gasbarri, Matteo V’kovski, Philip Torriani, Giulia Thiel, Volker Stellacci, Francesco Tapparel, Caroline Cagno, Valeria Microorganisms Communication Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) depends on angiotensin converting enzyme 2 (ACE2) for cellular entry, but it might also rely on attachment receptors such as heparan sulfates. Several groups have recently demonstrated an affinity of the SARS-CoV2 spike protein for heparan sulfates and a reduced binding to cells in the presence of heparin or heparinase treatment. Here, we investigated the inhibitory activity of several sulfated and sulfonated molecules, which prevent interaction with heparan sulfates, against vesicular stomatitis virus (VSV)-pseudotyped-SARS-CoV-2 and the authentic SARS-CoV-2. Sulfonated cyclodextrins and nanoparticles that have recently shown broad-spectrum non-toxic virucidal activity against many heparan sulfates binding viruses showed inhibitory activity in the micromolar and nanomolar ranges, respectively. In stark contrast with the mechanisms that these compounds present for these other viruses, the inhibition against SARS-CoV-2 was found to be simply reversible. MDPI 2020-11-30 /pmc/articles/PMC7760145/ /pubmed/33265927 http://dx.doi.org/10.3390/microorganisms8121894 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Gasbarri, Matteo V’kovski, Philip Torriani, Giulia Thiel, Volker Stellacci, Francesco Tapparel, Caroline Cagno, Valeria SARS-CoV-2 Inhibition by Sulfonated Compounds |
title | SARS-CoV-2 Inhibition by Sulfonated Compounds |
title_full | SARS-CoV-2 Inhibition by Sulfonated Compounds |
title_fullStr | SARS-CoV-2 Inhibition by Sulfonated Compounds |
title_full_unstemmed | SARS-CoV-2 Inhibition by Sulfonated Compounds |
title_short | SARS-CoV-2 Inhibition by Sulfonated Compounds |
title_sort | sars-cov-2 inhibition by sulfonated compounds |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760145/ https://www.ncbi.nlm.nih.gov/pubmed/33265927 http://dx.doi.org/10.3390/microorganisms8121894 |
work_keys_str_mv | AT gasbarrimatteo sarscov2inhibitionbysulfonatedcompounds AT vkovskiphilip sarscov2inhibitionbysulfonatedcompounds AT torrianigiulia sarscov2inhibitionbysulfonatedcompounds AT thielvolker sarscov2inhibitionbysulfonatedcompounds AT stellaccifrancesco sarscov2inhibitionbysulfonatedcompounds AT tapparelcaroline sarscov2inhibitionbysulfonatedcompounds AT cagnovaleria sarscov2inhibitionbysulfonatedcompounds |